Myeloproliferative neoplasm (MPN) is a chronic leukemia characterized with no curative treatments other than bone marrow transplantation. MPN results from the acquisition of a mutation in a blood stem cell that drives the unrestrained production of myeloid blood cells. Mutations in the gene calreticulin have been recently identified in a large proportion of MPN patients, it is currently unknown how calreticulin mutations drive MPN. Our goal is to identify the mechanism by which calreticulin mutations cause the manifestations of MPN and to develop drugs targeting calreticulin to treat this disease.
Location: University of CA, Irvine - California
Proposal: Pathogenesis of Calreticulin-Mutated Myeloproliferative Neoplasm